MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition

Molecular Imaging and Biology

Volumn 13, Issue 2, 2011, Pages 314-320

  Guimaraes, Alexander R ^a   Ross, Robert ^b   Figuereido, Jose L ^a   Waterman, Peter ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Magnetic nanoparticle imaging; Magnetic resonance imaging; MRI; mTOR; Renal cell cancer; Ultrasmall superparamagnetic iron oxide nanoparticle

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SORAFENIB; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; IMAGE ANALYSIS; IMAGE PROCESSING; KIDNEY CARCINOMA; LOW DRUG DOSE; MICROVASCULARIZATION; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; FERUMOXYTOL; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; MICROVESSELS; NANOPARTICLES; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

MAMMALIA; MUS MUSCULUS;

EID: 79955940812     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0357-2     Document Type: Article

References (24)

1. Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
2. Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
3. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
4. Jac J et al (2007) A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 25 (18S): 5107
5. Lamuraglia M et al (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472-2479
6. Marzola P et al (2004) In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10:739-750
7. Marzola P et al (2005) Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11:5827-5832
8. Del Bufalo D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554
9. Thomas GV et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127
10. Heng DY, Bukowski RM (2008) Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets 8:676-682
11. Lainakis G, Bamias A (2008) Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets 8:349-358
12. Lane HA et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15:1612-1622
13. Lee DF, Hung MC (2007) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 6:3011-3014
14. Mabuchi S et al (2007) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67:2408-2413
15. Szczylik C, Demkow T, Staehler M (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Proc Am Soc Clin Oncol Meet
16. Flaherty KT et al (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496-501
17. Rosen MA, Schnall MD (2007) Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 13:770s-776s
18. Schnell CR et al (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68:6598-6607
19. Bremer C et al (2003) Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology 226:214-220
20. Guimaraes AR et al (2008) Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model. Pancreas 37:440-444
21. Persigehl T et al (2007) Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology 244:449-456
22. Boxerman J et al (1995) MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34:555-566
23. Dennie J et al (1998) NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40:793-799
24. Tang Y et al (2005) In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res 65:8324-8330